ArticleTranslational vision science & technology2026
Uptake of Polygenic Risk Testing for Glaucoma in Unaffected Individuals.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Polygenic risk score for glaucoma is an emerging tool showing effective risk stratification. Previous studies have shown public acceptability for the test as a hypothetical scenario. However, the potential uptake of the test and associated predictors has not been reported. Methods: Individuals who had previously participated in a questionnaire-based study evaluating attitudes toward polygenic testing for glaucoma were invited to participate in a prospective research study for which they will undergo polygenic testing for glaucoma. Individuals had to be over the age of 50 years and living in South Australia to be eligible and invited to participate. Uptake was assessed by decision to consent to the research project and provide a sample for polygenic testing. Multivariable logistic regression was performed to identify predictor variables associated with uptake. Results: Of the 418 individuals who completed the initial questionnaire, 292 were eligible to participate, of which 143 enrolled, yielding an uptake rate of 49.0%. The mean age of the enrolled cohort was 67.5 years, 67.1% were female, 83.2% were from an urban residency, and 58.7% had a family history of glaucoma. Interest in testing was not associated with participation (P = 0.61). Predictors of uptake included a positive family history (P < 0.001) urban residency (P = 0.004), higher education (P = 0.036), and obtaining more information (P = 0.027). Conclusions: This is the first study to demonstrate the potential uptake of polygenic testing for glaucoma among an unaffected population. Translational Relevance: These findings provide useful insights into the predictors of glaucoma polygenic testing to support effective clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.